WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

CMB International Securities analyst Jill Wu has maintained their bullish stance on WXIBF stock, giving a Buy rating on January 13.Stay Ahead ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

Then on Jan. 6, affiliated company WuXi Biologics said its subsidiary WuXi Vaccines plans to sell its vaccine plant in ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop multi-payload antibody-drug conjugates. Analysts weighed in on whether ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

We cut our fair value estimate on narrow-moat-rated WuXi Biologics to HKD 24.60 per share ... WuXi divested a vaccine manufacturing site in Ireland, indicating reduced capacity planning.

Fabrice Baschiera, CEO of Substipharm Biologics, stated: "We are dedicated to providing high-quality vaccines to protect children from life-threatening diseases. With Vietnam facing a severe ...

WuXi Biologics employees have once again exemplified their deep-rooted commitment to the local community, delivering impactful support to St. Vincent de Paul Dundalk through their fourth annual ...

Wuxi Biologics Co. Ltd. is licensing a preclinical trispecific T-cell engager to Candid Therapeutics Inc. in a deal worth up to $925 million plus royalties.

Ireland is bracing for -20-degree weather on Thursday night as the country was under multiple weather warnings. Every county is under either a Status Orange or Yellow Low Temperature and Ice ...